Avidity Partners Management LP reported 43 positions worth $610.73M for the quarter ended Jun 30, 2026, up 39.2% on the prior quarter. It opened 7 new positions, added to 10, trimmed 6 and exited 9. Its largest holding is Dianthus Therapeutics, Inc. at 33.6% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| CGON CG Oncology, Inc. | +1.40M | – | $99.40M | 16.27% |
| IMUX Immunic, Inc. | +602.9K | +900.0% | $9.27M | 1.69% |
| SENS Senseonics Holdings, Inc. | +1.60M | – | $9.09M | 1.49% |
| ELVN Enliven Therapeutics, Inc. | +150.0K | +37.5% | $7.61M | 4.57% |
| JBIO Jade Biosciences, Inc. | +300.0K | +21.4% | $6.67M | 6.19% |
| KPTI Karyopharm Therapeutics Inc. | +460.7K | +99.4% | $4.50M | 1.48% |
| NVCT Nuvectis Pharma, Inc. | +200.0K | – | $3.68M | 0.602% |
| ALMR Alamar Biosciences, Inc. | +110.0K | – | $2.98M | 0.488% |
| GPCR Structure Therapeutics Inc. | +50.0K | +104.2% | $2.68M | 0.861% |
| TEM Tempus AI, Inc. | +40.0K | +61.5% | $2.32M | 0.996% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| HUM Humana Inc | -25.0K | -100.0% | $5.91M | Exited |
| MDT Medtronic plc | -30.0K | -30.0% | $2.35M | 0.897% |
| ICLR Icon Plc | -16.0K | -100.0% | $1.89M | Exited |
| NTRA Natera, Inc. | -9,000 | -100.0% | $1.86M | Exited |
| CORT Corcept Therapeutics Inc | -30.0K | -100.0% | $1.40M | Exited |
| HIMS Hims & Hers Health, Inc. | -50.0K | -100.0% | $1.36M | Exited |
| VIR Vir Biotechnology, Inc. | -100.0K | -16.1% | $1.02M | 0.866% |
| AVR Anteris Technologies Global Corp. | -150.0K | -100.0% | $922.50K | Exited |
| MLTX MoonLake Immunotherapeutics | -50.0K | -100.0% | $819.00K | Exited |
| PTON Peloton Interactive, Inc. | -100.0K | -50.0% | $591.00K | 0.097% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| CGON CG Oncology, Inc. | +1.40M | $99.40M | 16.27% |
| SENS Senseonics Holdings, Inc. | +1.60M | $9.09M | 1.49% |
| NVCT Nuvectis Pharma, Inc. | +200.0K | $3.68M | 0.602% |
| ALMR Alamar Biosciences, Inc. | +110.0K | $2.98M | 0.488% |
| AVLN Avalyn Pharma Inc. | +60.0K | $1.98M | 0.323% |
| KLRA Kailera Therapeutics, Inc. | +80.0K | $1.76M | 0.289% |
| EVMN Evommune, Inc. | +75.0K | $996.75K | 0.163% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| HUM Humana Inc | -25.0K | $5.91M | 1.35% |
| ICLR Icon Plc | -16.0K | $1.89M | 0.431% |
| NTRA Natera, Inc. | -9,000 | $1.86M | 0.423% |
| CORT Corcept Therapeutics Inc | -30.0K | $1.40M | 0.318% |
| HIMS Hims & Hers Health, Inc. | -50.0K | $1.36M | 0.31% |
| AVR Anteris Technologies Global Corp. | -150.0K | $922.50K | 0.21% |
| MLTX MoonLake Immunotherapeutics | -50.0K | $819.00K | 0.187% |
| ABUS Arbutus Biopharma Corp | -125.0K | $525.00K | 0.12% |
| ACAD Acadia Pharmaceuticals Inc | -13.0K | $291.11K | 0.066% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | DNTH Dianthus Therapeutics, Inc. | Healthcare | 2.10M | $205.12M | 33.59% | 0 | 0.0% | Unchanged | 3.76% |
| 2 | CGON CG Oncology, Inc. | Healthcare | 1.40M | $99.40M | 16.27% | +1.40M | – | New | 1.58% |
| 3 | ORKA Oruka Therapeutics, Inc. | Healthcare | 760.4K | $72.37M | 11.85% | 0 | 0.0% | Unchanged | 1.21% |
| 4 | JBIO Jade Biosciences, Inc. | Healthcare | 1.70M | $37.79M | 6.19% | +300.0K | +21.4% | Added | 2.68% |
| 5 | ELVN Enliven Therapeutics, Inc. | Healthcare | 550.0K | $27.91M | 4.57% | +150.0K | +37.5% | Added | 0.75% |
| 6 | CATX Perspective Therapeutics, Inc. | Healthcare | 6.30M | $21.48M | 3.52% | +250.0K | +4.1% | Added | 5.22% |
| 7 | AKTS Aktis Oncology, Inc. | Healthcare | 484.2K | $15.61M | 2.56% | +15.6K | +3.3% | Added | 0.88% |
| 8 | PVLA Palvella Therapeutics, Inc. | Healthcare | 70.0K | $10.70M | 1.75% | 0 | 0.0% | Unchanged | 0.49% |
| 9 | RGEN Repligen Corp | Healthcare | 77.8K | $10.62M | 1.74% | 0 | 0.0% | Unchanged | 0.14% |
| 10 | IMUX Immunic, Inc. | Healthcare | 669.9K | $10.30M | 1.69% | +602.9K | +900.0% | Added | 1.58% |
| 11 | SENS Senseonics Holdings, Inc. | Healthcare | 1.60M | $9.09M | 1.49% | +1.60M | – | New | 2.77% |
| 12 | KPTI Karyopharm Therapeutics Inc. | Healthcare | 924.5K | $9.03M | 1.48% | +460.7K | +99.4% | Added | 3.19% |
| 13 | TEVA Teva Pharmaceutical Industries Ltd | Healthcare | 200.0K | $6.78M | 1.11% | 0 | 0.0% | Unchanged | 0.02% |
| 14 | DXCM Dexcom Inc | Healthcare | 100.0K | $6.74M | 1.1% | 0 | 0.0% | Unchanged | 0.03% |
| 15 | TEM Tempus AI, Inc. | Healthcare | 105.0K | $6.08M | 0.996% | +40.0K | +61.5% | Added | 0.06% |
Tip. Select a row to see that position’s full history at Avidity Partners Management.
As of its Q2 2026 13F filing, Avidity Partners Management LP’s five largest positions were Dianthus Therapeutics, Inc. (DNTH) at 33.6%, CG Oncology, Inc. (CGON) at 16.3%, Oruka Therapeutics, Inc. (ORKA) at 11.9%, Jade Biosciences, Inc. (JBIO) at 6.2%, Enliven Therapeutics, Inc. (ELVN) at 4.6% of the reported portfolio.
Avidity Partners Management LP reported a 13F portfolio worth $610.73M across 43 positions for Q2 2026. That is up 39.2% from the previous quarter.
Its largest purchases by value were CG Oncology, Inc. ($99.40M), Immunic, Inc. ($9.27M), Senseonics Holdings, Inc. ($9.09M). It opened 7 new positions.
Its largest sales by value were Humana Inc ($5.91M), Medtronic plc ($2.35M), Icon Plc ($1.89M). It exited 9 positions entirely.
From the Form 13F-HR reports Avidity Partners Management LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.